Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176584 | 0.82 | MAOA (0.41) | ACLYMAOAMAOBALDH1A1KCNA3 | |
| SCHEMBL9883903 | 0.82 | TSHR (0.38) | ACLYMAOAMAOBTSHRLMNA | |
| SCHEMBL1153742 | 0.81 | ACLY (0.39) | ACLYMAOAMAOBPOLBCYP3A4 | |
| SCHEMBL9883927 | 0.80 | CNR2 (0.39) | ALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL2434431 | 0.79 | MAOA (0.43) | ACLYMAOAMAOBKCNA3ELANE | |
| SCHEMBL812046 | 0.79 | NPC1 (0.41) | ACLYMAOAMAOBPOLBKCNA3 | |
| SCHEMBL1812246 | 0.76 | MAOB (0.41) | ACLYMAOAMAOBLMNAPOLB | |
| SCHEMBL5232820 | 0.75 | MAOA (0.48) | ACLYMAOAMAOBALDH1A1KCNA3 | |
| SCHEMBL13097105 | 0.74 | ABL1 (0.37) | ACLYMAOAMAOBTSHRLMNA | |
| SCHEMBL7098191 | 0.70 | MAOA (0.41) | ACLYMAOAMAOBALDH1A1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673818-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSCHAFT (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8673818-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSCHAFT (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8673818-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSCHAFT (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8334300-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSHAFT (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334300-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSHAFT (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334300-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSHAFT (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120238450-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238450-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238450-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8193120-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSCHAFT (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20110143943-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110143943-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-7915282-B2 | Preparation by intramolecular cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7915282-B2 | Preparation by intramolecular cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 2011-03-29 | — | — | US | disclosed |
| US-7915282-B2 | Preparation by intramolecular cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 2011-03-29 | — | — | US | disclosed |
| EP-1280770-B1 | C 2? PHENYL-SUBSTITUTED CYCLIC KETO-ENOLS USED AS PESTICIDES AND HERBICIDES | BAYER AG (DE) | 2010-06-23 | — | — | EP | disclosed |
| EP-1280770-B1 | C 2? PHENYL-SUBSTITUTED CYCLIC KETO-ENOLS USED AS PESTICIDES AND HERBICIDES | BAYER AG (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-20030216260-A1 | C2-phenyl-substituted cyclic keto-enols used as pesticides and herbicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
| EP-1280770-A1 | C 2? PHENYL-SUBSTITUTED CYCLIC KETO-ENOLS USED AS PESTICIDES AND HERBICIDES | Bayer Aktiengesellschaft (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001074770-A1 | C2 PHENYL-SUBSTITUTED CYCLIC KETO-ENOLS USED AS PESTICIDES AND HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216260-A1 | C2-phenyl-substituted cyclic keto-enols used as pesticides and herbicides | PDHX, AKR1C3, AKR1A1 | ACLY 346/4885MAOA 2861/4885MAOB 2622/4885 |
| US-20110143943-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | AKR1C3, PDHX, AKR1C2 | ACLY 256/4885MAOA 2558/4885MAOB 2059/4885 |
| US-20120238450-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | AKR1C3, AKR1C4, AKR1C2 | ACLY 1114/4885MAOA 3712/4885MAOB 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.